StreetInsider.com News Articles

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, September 9, 2026, at 8:35 a.m. ET at the 2026 Cantor Global Healthcare Conference in New York, NY.

The live and archived webcast of this event can be accessed

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

The live and archived webcast of this event can be accessed

Acrivon Therapeutics names Michaela Levin as chief business officer

Mon, 31 Aug 2026 08:32:35 -0400

Acrivon Therapeutics (NASDAQ: ACRV) has appointed Michaela Levin, Ph.D., as chief business officer, effective Aug. 31, 2026, according to a company statement.

Levin most recently served as vice president of business development at Recursion, formerly Exscientia, where she led the acquisition of full rights to the ENPP1 inhibitor REV102 from Rallybio and negotiated multiple strategic term sheets. Before that, she was vice president of product intelligence and business development at Editas Medicine, where she negotiated licensing transactions including a Cas9 gene-editing technology license with Vertex Pharmaceuticals.

Earlier in her career, Levin held business development roles at Ovid Therapeutics, where she negotiated an

Acrivon Therapeutics names Michaela Levin as chief business officer

Mon, 31 Aug 2026 08:32:35 -0400

Acrivon Therapeutics (NASDAQ: ACRV) has appointed Michaela Levin, Ph.D., as chief business officer, effective Aug. 31, 2026, according to a company statement.

Earlier in her career, Levin held business development roles at Ovid Therapeutics, where she negotiated an

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Mon, 31 Aug 2026 08:30:00 -0400

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the appointment of Michaela Levin, Ph.D., as chief business officer, effective August 31, 2026. Dr. Levin comes with a solid, broad background in biotechnology business development, corporate strategy and transactional execution spanning mergers

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Mon, 31 Aug 2026 08:30:00 -0400

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy

Form 4 Acrivon Therapeutics, For: Aug 25 Filed by: Blume-Jensen Peter

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990085.html

Form 4 Acrivon Therapeutics, For: Aug 25 Filed by: Blume-Jensen Peter

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990085.html

Form 144 Acrivon Therapeutics, Filed by: Blume-Jensen Peter

Tue, 25 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26976116.html

Form 144 Acrivon Therapeutics, Filed by: Blume-Jensen Peter

Tue, 25 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26976116.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Peterson Katharine

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956269.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Peterson Katharine

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956269.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Miller Mary

Thu, 20 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260820/26956246.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Miller Mary

Thu, 20 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260820/26956246.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Devroe Eric

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956224.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Devroe Eric

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956224.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Gamelin Erick

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956231.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Gamelin Erick

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956231.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Blume-Jensen Peter

Thu, 20 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260820/26956207.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Blume-Jensen Peter

Thu, 20 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260820/26956207.html

Form SCHEDULE 13G/A Acrivon Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Thu, 13 Aug 2026 11:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26918677.html

Form SCHEDULE 13G/A Acrivon Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Thu, 13 Aug 2026 11:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26918677.html

Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c

Wed, 12 Aug 2026 17:23:08 -0400

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.43), $0.21 better than the analyst estimate of ($0.64).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

Form S-8 Acrivon Therapeutics,

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913691.html

Form S-8 Acrivon Therapeutics,

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913691.html